Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04904536 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Study acronym: STRONGER
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 2024 to Jun 30, 2025 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 400 to confirmed 190 · Completion date: Dec 2024 to Jul 30, 2025 · 1 morev6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 190
    • Completion date: Dec 2024 to Jul 30, 2025
    • Site details revised
  2. Secondary endpoints: details revised at 1 of 1 entry Study description expanded, about 10 words · Collaborators: 4 to 6 · Eligibility criteria expanded, about 5 wordsv5 Show 3 more changesShow less
    • Study description expanded, about 10 words
    • Collaborators: 4 to 6
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jan 2023 to Dec 2024 Completion date: Jun 2023 to Dec 2024 · Eligibility criteria expanded, about 17 wordsv4 Show 2 more changesShow less
    • Completion date: Jun 2023 to Dec 2024
    • Eligibility criteria expanded, about 17 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 11, 2021 to Mar 10, 2022 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Oct 11, 2021 to Mar 10, 2022
    • Site details revised
  5. Start date: Jun 2021 to Oct 11, 2021v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.
Trial Details
NCT Number NCT04904536
Lead Sponsor The George Institute
Collaborators: University of Sydney, Monash University, The Alfred, Universidad del Desarrollo, Chinese University of Hong Kong, Clinica Alemana de Santiago
Conditions Neurocognitive Impairment, Mild
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov